Clinical Trials
31
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (30 trials with phase data)• Click on a phase to view related trials
Continuation Study for Latozinemab
- First Posted Date
- 2023-11-01
- Last Posted Date
- 2025-02-07
- Lead Sponsor
- Alector Inc.
- Target Recruit Count
- 35
- Registration Number
- NCT06111014
- Locations
- 🇺🇸
Dignity Health - Arizona, Phoenix, Arizona, United States
🇺🇸Mayo Comprehensive Cancer Center - PPDS, Rochester, Minnesota, United States
🇺🇸Irving Institute for Clinical and Translational Research, New York, New York, United States
A Long-term Extension Study to Evaluate Safety, Tolerability, and Efficacy of AL002 in Alzheimer's Disease
- First Posted Date
- 2023-02-27
- Last Posted Date
- 2025-03-13
- Lead Sponsor
- Alector Inc.
- Target Recruit Count
- 198
- Registration Number
- NCT05744401
- Locations
- 🇺🇸
Banner Alzheimer's Institute, Phoenix, Arizona, United States
🇺🇸Georgetown University Medical Center, Washington, District of Columbia, United States
🇺🇸SFM Clinical Research, LLC, Boca Raton, Florida, United States
A Phase 2 Study to Evaluate AL001 in C9orf72-Associated ALS
- First Posted Date
- 2021-09-22
- Last Posted Date
- 2025-06-18
- Lead Sponsor
- Alector Inc.
- Target Recruit Count
- 5
- Registration Number
- NCT05053035
- Locations
- 🇺🇸
University of South Florida, Tampa, Florida, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Washington University School of Medicine, Saint Louis, Missouri, United States
A Phase 2 Study to Evaluate Efficacy and Safety of AL002 in Participants With Early Alzheimer's Disease
- First Posted Date
- 2020-10-19
- Last Posted Date
- 2024-08-27
- Lead Sponsor
- Alector Inc.
- Target Recruit Count
- 328
- Registration Number
- NCT04592874
- Locations
- 🇺🇸
Banner Alzheimer's Institute, Phoenix, Arizona, United States
🇺🇸Woodlands Research Network, LLC - ERG, Rogers, Arkansas, United States
🇺🇸ATP Clinical Research, Costa Mesa, California, United States
A Phase 3 Study to Evaluate Efficacy and Safety of AL001 in Frontotemporal Dementia (INFRONT-3)
- Conditions
- Frontotemporal Dementia
- Interventions
- First Posted Date
- 2020-05-05
- Last Posted Date
- 2025-06-08
- Lead Sponsor
- Alector Inc.
- Target Recruit Count
- 110
- Registration Number
- NCT04374136
- Locations
- 🇺🇸
Dignity Health, Phoenix, Arizona, United States
🇺🇸University of California San Diego, La Jolla, California, United States
🇺🇸University of Colorado, Aurora, Colorado, United States
- Prev
- 1
- 2
- Next